Cube Pharmaceuticals: Obtained the registration certificate of Mesalazine Enteric-coated Tablets.

On the evening of July 31, Cub Pharmaceuticals announced that the company has recently received the "Drug Registration Certificate" issued by the National Medical Products Administration for Mesalazine Enteric-coated Tablets. Mesalazine Enteric-coated Tablets release mesalazine in the intestines after oral administration, and are used for the treatment of acute exacerbations of ulcerative colitis and for maintenance therapy to prevent recurrence, as well as for the treatment of acute exacerbations of Crohn's disease.